Ayala Pharmaceuticals, Inc. ADXS
At closeFeb 4, 2026, 4:00 PM EST
- YTD
- +1,405.11%
- 1 year
- +2,014.01%
- Market cap
- 22.57M
- Revenue (ttm)
- 3.24M
- EPS (ttm)
- -0.171
- Shares out
- 145.64M
- P/E ratio
- -0.08
- Forward P/E
- -1.03
- YTD return
- +1405.11%
- 1-year return
- +2014.01%
- Volume
- 10.01K
- Avg volume
- 4.28M
- Open
- 0.0996
- Previous close
- 0.60355
- Day's range
- 0.0846 – 0.60355
- 52-week range
- 0.121 – 1.57
- Beta
- 2.05
- Analysts
- Buy
- Earnings date
- Feb 19, 2024
2Y +0.0136 (+2.31%)
Key statistics
- Enterprise value
- -21.95M
- PEG ratio
- 0.00
- Price / sales
- 6.97
- Price / book
- 0.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.02M
- Total cash
- 45.26M
- Total debt
- 0
- Return on equity
- -49.85%
- Short % of float
- 2.15%
- 50-day average
- 0.31906
- 200-day average
- 0.445205
Analyst view
Consensus: buy
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 19, 2024
Expected Feb 19, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 19, 2024 | Jan 1, 2024 | 0.00 | — | — | — |
| May 4, 2023 | Jan 1, 2023 | 0.00 | — | — | — |
| Sep 12, 2022 | Jul 1, 2022 | 0.00 | -3.83 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2020 | H.C. Wainwright | down | Buy | Neutral |
| Nov 25, 2020 | Jefferies | down | Buy | Hold |
| Nov 25, 2020 | H.C. Wainwright | main | Buy | Buy |
| Nov 25, 2020 | Cantor Fitzgerald | main | Overweight | Overweight |
| Nov 25, 2020 | Barclays | main | — | Overweight |
| Nov 25, 2020 | Barclays | main | — | Overweight |
About Ayala Pharmaceuticals, Inc.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- advaxis.com
News
Aadi Bioscience (NASDAQ:AADI) and Ayala Pharmaceuticals (NASDAQ:ADXS) Head to Head Analysis 
Head-To-Head Survey: Evofem Biosciences (NASDAQ:EVFM) and Ayala Pharmaceuticals (NASDAQ:ADXS) 
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals 
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline 
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline 
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations 
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome 
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 
Ayala Pharmaceuticals Announces Closing of Merger with Biosight 
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Your note
Sign in to keep a note on ADXS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APPEL RONI A | Director | Sale | Mar 12, 2020 | 0 |
| BERLIN KENNETH A | Chief Executive Officer | Stock Award(Grant) | Apr 7, 2019 | 4,000 |
| BERMAN RICHARD J | Director | Stock Award(Grant) | Jun 25, 2018 | 55,669 |
| BONSTEIN SARA M | Chief Financial Officer | Stock Award(Grant) | Mar 28, 2018 | 226,670 |
| GUTIERREZ ANDRES A. | Officer | Stock Award(Grant) | Apr 10, 2019 | 3,750 |
| HENDERSON MOLLY | Chief Financial Officer | Stock Award(Grant) | Apr 10, 2019 | 5,833 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 4.09% | 5,957,642 | 3.11M | Sep 29, 2021 |
| Blackrock Inc. | 0.86% | 1,257,252 | 655.66K | Sep 29, 2021 |
| Geode Capital Management, LLC | 0.78% | 1,135,533 | 592.18K | Sep 29, 2021 |
| State Street Corporation | 0.26% | 385,064 | 200.81K | Sep 29, 2021 |
| Northern Trust Corporation | 0.17% | 252,877 | 131.88K | Sep 29, 2021 |
| Millennium Management LLC | 0.17% | 244,970 | 127.75K | Sep 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.82% | 4,102,475 | 2.14M | Sep 29, 2021 |
| Vanguard Extended Market Index Fund | 1.14% | 1,663,811 | 867.68K | Sep 29, 2021 |
| Fidelity Extended Market Index Fund | 0.52% | 753,761 | 365.27K | Oct 30, 2021 |
| Price (T.Rowe) U.S. Equities Trust | 0.11% | 166,748 | 86.96K | Sep 29, 2021 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.11% | 159,787 | 77.43K | Oct 30, 2021 |
| Fidelity NASDAQ Composite Index Fund | 0.09% | 132,082 | 64.01K | Oct 30, 2021 |